Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
The Nucleolus02:55

The Nucleolus

8.9K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.9K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
RNA Interference01:23

RNA Interference

26.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interplay of microRNAs and circRNAs in Epithelial Ovarian Cancer.

Non-coding RNA·2024
Same author

Characterization of immunologically detectable T-cell sensitization, Immunohistochemical detection of pro-inflammatory cytokines, and clinical parameters of patients after allogeneic intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans.

BMC oral health·2022
Same author

The History and Future of Basic and Translational Cell-Free DNA Research at a Glance.

Diagnostics (Basel, Switzerland)·2022
Same author

MicroRNAs and their Implications in CD4+ T-cells, Oligodendrocytes and Dendritic Cells in Multiple Sclerosis Pathogenesis.

Current molecular medicine·2022
Same author

Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients.

Cancer drug resistance (Alhambra, Calif.)·2022
Same author

Circulating non-coding RNAs in recurrent and metastatic ovarian cancer.

Cancer drug resistance (Alhambra, Calif.)·2022

Related Experiment Video

Updated: Jul 30, 2025

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.8K

Interplay between LncRNAs and microRNAs in Breast Cancer.

Heidi Schwarzenbach1, Peter B Gahan2

  • 1Department of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

International Journal of Molecular Sciences
|May 13, 2023
PubMed
Summary
This summary is machine-generated.

Long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) interact in breast cancer, influencing drug resistance. Understanding this interplay could lead to new therapies to overcome chemoresistance.

Keywords:
breast cancercancer detection rateslong non-coding RNAsmicroRNAs

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.3K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.7K

Related Experiment Videos

Last Updated: Jul 30, 2025

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.8K
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.3K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.7K

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • Long noncoding RNAs (lncRNAs) can act as competing endogenous RNAs (ceRNAs) and modulate microRNA (miRNA) activity.
  • The precise interplay between lncRNAs and miRNAs and its role in cancer drug resistance is not fully understood.
  • MicroRNAs (miRNAs) have known oncogenic and tumor-suppressive functions, but the impact of lncRNAs on miRNAs in this context requires further investigation.

Purpose of the Study:

  • To investigate the regulatory network between lncRNAs and miRNAs in post-transcriptional regulation.
  • To determine the impact of this lncRNA-miRNA interplay on chemoresistance in breast cancer treatment.
  • To explore how understanding this interaction can aid in developing novel therapeutic strategies.

Main Methods:

  • Extensive literature search across multiple scientific databases, including PubMed.
  • Analysis of regulatory post-transcriptional networks involving lncRNAs and miRNAs.
  • Focus on the context of breast cancer and its response to chemotherapeutic drugs.

Main Results:

  • The study highlights the complex interactions between lncRNAs and miRNAs in post-transcriptional gene regulation.
  • Evidence suggests this interplay significantly influences the efficacy of chemotherapeutic agents in breast cancer.
  • The findings underscore the importance of considering both lncRNAs and miRNAs in understanding drug resistance mechanisms.

Conclusions:

  • The interplay between lncRNAs and miRNAs is a critical factor in breast cancer chemoresistance.
  • Targeting the lncRNA-miRNA regulatory network may offer new avenues for overcoming drug resistance.
  • Further research into this interaction holds promise for the development of more effective breast cancer therapies.